Interobserver Agreement for Estrogen Receptor Immunohistochemical Analysis in Breast Cancer: A Comparison of Manual and Computer-Assisted Scoring Methods

Annals of Diagnostic Pathology

Volumn 8, Issue 1, 2004, Pages 23-27

  Diaz, Leslie K ^b   Sahin, Aysegul ^b   Sneige, Nour ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

Estrogen receptor; Image analysis; Immunohistochemistry; Interobserver agreement

Indexed keywords

ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6F11; UNCLASSIFIED DRUG;

ARTICLE; BREAST; BREAST CANCER; COMPUTER PROGRAM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCORING SYSTEM; UNITED STATES;

EID: 1042301335     PISSN: 10929134     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2003.11.004     Document Type: Article

References (21)

1. Bezwoda WR, Esser JD, Dansey R, et al: The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 1991;68:867-872
2. Fisher BJ, Perera FE, Cooke AL, et al: Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: Patterns of recurrence. Int J Radiat Oncol Biol Phys 1998;42:117-123
3. Cooke AL, Perera F, Fisher B, et al: Tamoxifen with and without radiation after partial mastectomy in patients with involved nodes. Int J Radiat Oncol Biol Phys 1995;31:777-781
4. Elledge RM, Green S, Pugh R, et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 2000;89:111-117
5. Layfield LJ, Gupta D, Mooney EE: Assessment of tissue estrogen and progesterone receptor levels: A survey of current practice, techniques, and quantitation methods. Breast. J 2000; 6:189-196
6. Fitzgibbons PL, Page DL, Weaver D, et al: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-978
7. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001;19: 3817-3827
8. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481
9. Swain SM: Tamoxifen for patients with estrogen receptor-negative breast cancer. J Clin Oncol 2001;19:93S-97S
10. Charpin C, Martin PM, Jacquemier J, et al: Estrogen receptor immunocytochemical assay (ER-ICA): Computerized image analysis system, immunoelectron microscopy, and comparisons with estradiol binding assays in 115 breast carcinomas. Cancer Res 1986;46:4271s-4277s
11. Esteban JM, Ahn C, Battifora H, et al: Quantitative immunohistochemical assay for hormonal receptors: Technical aspects and biological significance. J Cell Biochem Suppl 1994;19: 138-145
12. Esteban JM, Battifora H, Warsi Z, et al: Quantification of estrogen receptors on paraffin-embedded tumors by image analysis. Mod Pathol 1991;4:53-57
13. Layfield LJ, Saria EA, Conlon DH, et al: Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: Prognostic significance. J Surg Oncol 1996;61:177-184
14. Nichols GE, Frierson HF Jr, Boyd JC, et al: Automated immunohistochemical assay for estrogen receptor status in breast cancer using monoclonal antibody CC4-5 on the Ventana ES. Am J Clin Pathol 1996;106:332-338
15. Castagnetta LA, Traina A, Liquori M, et al: Quantitative image analysis of estrogen and progesterone receptors as a prognostic tool for selecting breast cancer patients for therapy. Anal Quant Cytol Histol 1999;21:59-62
16. Layfield LJ, Saria E, Mooney EE, et al: Tissue heterogeneity of immunohistochemically detected estrogen receptor. Implications for image analysis quantification. Am J Clin Pathol 1998;110:758-764
17. Kohlberger PD, Breitenecker F, Kaider A, et al: Modified true-color computer-assisted image analysis versus subjective scoring of estrogen receptor expression in breast cancer: A comparison. Anticancer Res 1999;19:2189-2193
18. Mofidi R, Walsh R, Ridgway PF, et al: Objective measurement of breast cancer oestrogen receptor status through digital image analysis. Eur J Surg Oncol 2003;29:20-24
19. Chebil G, Bendahl PO, Ferno M: Estrogen and progesterone receptor assay in paraffin-embedded breast cancer - Reproducibility of assessment. Acta Oncol 2003;42:43-47
20. Bevitt DJ, Milton ID, Piggot N, et al: New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry. J Pathol 1997;183:228-232
21. Pertschuk LP, Feldman JG, Kim YD, et al: Estrogen receptor immunocytochemistry in paraffin embedded tissues with ERID5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer 1996;77:2514-2519